Javascript must be enabled to continue!
Computational approach for counting of SISH amplification signals for HER2 status assessment
View through CrossRef
The human epidermal growth factor receptor 2 (HER2) gene is a critical biomarker for determining amplification status and targeting clinical therapies in breast cancer treatment. This study introduces a computer-aided method that automatically measures and scores HER2 gene status from invasive tissue regions of breast cancer using whole slide images (WSI) through silver
in situ
hybridization (SISH) staining. Image processing and deep learning techniques are employed to isolate untruncated and non-overlapping single nuclei from cancer regions. The Stardist deep learning model is fine-tuned on our HER2-SISH data to identify nuclei regions, followed by post-processing based on identified HER2 and CEP17 signals. Conventional thresholding techniques are used to segment HER2 and CEP17 signals. HER2 amplification status is determined by calculating the HER2-to-CEP17 signal ratio, in accordance with ASCO/CAP 2018 standards. The proposed method significantly reduces the effort and time required for quantification. Experimental results demonstrate a 0.91% correlation coefficient between pathologists manual enumeration and the proposed automatic SISH quantification approach. A one-sided paired t-test confirmed that the differences between the outcomes of the proposed method and the reference standard are statistically insignificant, with p-values exceeding 0.05. This study illustrates how deep learning can effectively automate HER2 status determination, demonstrating improvements over current manual methods and offering a robust, reproducible alternative for clinical practice.
Title: Computational approach for counting of SISH amplification signals for HER2 status assessment
Description:
The human epidermal growth factor receptor 2 (HER2) gene is a critical biomarker for determining amplification status and targeting clinical therapies in breast cancer treatment.
This study introduces a computer-aided method that automatically measures and scores HER2 gene status from invasive tissue regions of breast cancer using whole slide images (WSI) through silver
in situ
hybridization (SISH) staining.
Image processing and deep learning techniques are employed to isolate untruncated and non-overlapping single nuclei from cancer regions.
The Stardist deep learning model is fine-tuned on our HER2-SISH data to identify nuclei regions, followed by post-processing based on identified HER2 and CEP17 signals.
Conventional thresholding techniques are used to segment HER2 and CEP17 signals.
HER2 amplification status is determined by calculating the HER2-to-CEP17 signal ratio, in accordance with ASCO/CAP 2018 standards.
The proposed method significantly reduces the effort and time required for quantification.
Experimental results demonstrate a 0.
91% correlation coefficient between pathologists manual enumeration and the proposed automatic SISH quantification approach.
A one-sided paired t-test confirmed that the differences between the outcomes of the proposed method and the reference standard are statistically insignificant, with p-values exceeding 0.
05.
This study illustrates how deep learning can effectively automate HER2 status determination, demonstrating improvements over current manual methods and offering a robust, reproducible alternative for clinical practice.
Related Results
Human Epidermal Growth Factor Receptor-2(HER-2) expression in Sri Lankan gastric adenocarcinoma patients: An analysis of the concordance of HER2 expression and survival based on silver in-situ hybridization (SISH)
Human Epidermal Growth Factor Receptor-2(HER-2) expression in Sri Lankan gastric adenocarcinoma patients: An analysis of the concordance of HER2 expression and survival based on silver in-situ hybridization (SISH)
Abstract
Background: Accurate HER2 status is crucial for gastric adenocarcinoma (GC) patient selection for antiHER2 therapy. It is assessed immunohistochemically (IHC) for ...
Abstract P4-15-07: HER2 positive (HER2/CEP17 ratio≥2.0) invasive mammary carcinomas with average <4.0 HER2 and <2.0 CEP17 signals/cell: Clinicopathologic features, correlation with HER2 immunohistochemistry and response to neoadjuvant chemot
Abstract P4-15-07: HER2 positive (HER2/CEP17 ratio≥2.0) invasive mammary carcinomas with average <4.0 HER2 and <2.0 CEP17 signals/cell: Clinicopathologic features, correlation with HER2 immunohistochemistry and response to neoadjuvant chemot
Abstract
Background: ASCO/CAP guidelines for the determination of HER2 amplification have recently been revised in an attempt to clarify which patients will benefit ...
Abstract P4-13-22: Successful targeting HER2 in heavily pretreated HER2-negative metastatic breast cancer patients presenting with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells
Abstract P4-13-22: Successful targeting HER2 in heavily pretreated HER2-negative metastatic breast cancer patients presenting with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells
Abstract
Background: A considerable proportion of patients (pts) with HER2-negative (HER2-) metastatic breast cancer (MBC) present with elevated serum levels of the ...
HER2 expression dynamics and prognostic significance in the treatment of gastric cancer.
HER2 expression dynamics and prognostic significance in the treatment of gastric cancer.
4025
Background:
The human epidermal growth factor receptor 2 (HER2) expression undergoes changes during the treatment of gastric canc...
HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and Outcome
HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and Outcome
Abstract
Aims
Apocrine carcinoma of the breast (APO) expresses HER2 in 30-50% of cases. This study explored the clinicopathological features and outcome of HER2+ APO (HER2...
Abstract P3-09-02: The HER2 –positive subtypes by stage and race/ethnicity
Abstract P3-09-02: The HER2 –positive subtypes by stage and race/ethnicity
Abstract
HER2-positivity is often associated with poor survival. The purpose of this study is to determine if there are differences in mortality among the HER-positi...
Use of multimodal circulating tumor cell assay to detect HER2-ultralow and ER co-expression matched with single-cell chromosomal instability in metastatic breast cancer.
Use of multimodal circulating tumor cell assay to detect HER2-ultralow and ER co-expression matched with single-cell chromosomal instability in metastatic breast cancer.
e13024
Background:
Breast cancer is the second leading cause of cancer-related mortality among US women, with metastatic breast cancer...
Abstract P4-04-05: circHEACA promotes anti-HER2 drug resistance by HEACA-GRB7/AKT axis in HER2+ breast cancer patients
Abstract P4-04-05: circHEACA promotes anti-HER2 drug resistance by HEACA-GRB7/AKT axis in HER2+ breast cancer patients
Abstract
Background: Some HER2-positive (HER2+) breast cancer patient are resistant to anti-HER2 therapy, and the potential reasons of anti-HER2 drug resistance rema...

